Investment Centers of America Inc. increased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 15.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 78,758 shares of the biopharmaceutical company’s stock after acquiring an additional 10,736 shares during the quarter. Investment Centers of America Inc.’s holdings in Bristol-Myers Squibb were worth $4,265,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Ameriprise Financial Inc. lifted its stake in shares of Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after acquiring an additional 2,451,390 shares during the period. Swiss National Bank lifted its stake in shares of Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after acquiring an additional 1,267,900 shares during the period. State Street Corp lifted its stake in shares of Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the period. Karp Capital Management Corp acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at $38,890,000. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Bristol-Myers Squibb by 23.8% during the first quarter. Canada Pension Plan Investment Board now owns 3,362,609 shares of the biopharmaceutical company’s stock valued at $182,859,000 after acquiring an additional 646,000 shares during the period. 68.80% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently issued reports on BMY shares. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price target on the stock in a research note on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. BMO Capital Markets reaffirmed an “underperform” rating and set a $47.00 price target (down previously from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Finally, Leerink Swann dropped their price objective on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $62.54.
Shares of Bristol-Myers Squibb Company (NYSE BMY) traded down 0.35% during midday trading on Friday, hitting $62.62. The company’s stock had a trading volume of 6,579,322 shares. The company has a market cap of $102.69 billion, a P/E ratio of 22.87 and a beta of 1.18. The company has a 50-day moving average price of $57.53 and a 200 day moving average price of $55.70. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $63.47.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.69 EPS. On average, equities research analysts predict that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.